Selexis SA and NKT Therapeutics (NKTT) have entered into a research services agreement under which Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their INTEGRA-D2M platform. The platform enables the rapid isolation of production cell lines associated with the selection of lead compounds from libraries of protein variants expressed in Chinese Hamster Ovary (CHO) cells. The selected CHO-based protein variant expressing clone can then be used directly for cGMP manufacturing, according to the company

“We are excited about the partnership with NKTT, who are recognized as leaders in the biology and therapeutic applications for modulating Natural Killer T cells,” said Dr. Igor Fisch, chief executive officer and co-founder of Selexis SA. “Our novel and powerful INTEGRA-D2M platform, is able to support NKTT in rapidly making their final product decision while we also develop and deliver a high-performance production cell line ready for cGMP manufacturing.”

“We greatly appreciate working with the team at Selexis and utilizing their powerful technology platform,” adds Dr. Alem Truneh, chief scientific officer and co-founder of NKTT.

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference